Literature DB >> 17287242

Estimates of the cancer incidence and mortality in Europe in 2006.

J Ferlay1, P Autier, M Boniol, M Heanue, M Colombet, P Boyle.   

Abstract

BACKGROUND: Monitoring the evolution of the cancer burden in Europe is of great value. Estimates of the cancer burden in Europe have been published for 2004 and estimates are now being presented for cancer incidence and mortality in Europe for 2006.
METHODS: The most recent sources of cancer incidence and mortality data have been collected and projections have been carried out using short-term prediction methods to produce estimated rates for 2006. Additional estimation was required where national incidence data were not available, and the method involved the projection of the aggregations of cancer incidence and mortality data from representative cancer registries. The estimated 2006 rates were applied to the corresponding estimated country population to obtain the best estimates of the cancer incidence and mortality in Europe in 2006.
RESULTS: In 2006 in Europe, there were an estimated 3,191,600 cancer cases diagnosed (excluding nonmelanoma skin cancers) and 1,703,000 deaths from cancer. The most common form of cancers was breast cancer (429,900 cases, 13.5% of all cancer cases), followed by colorectal cancers (412,900, 12.9%) and lung cancer (386,300, 12.1%). Lung cancer, with an estimated 334,800 deaths (19.7% of total), was the most common cause of death from cancer, followed by colorectal (207,400 deaths), breast (131,900) and stomach (118,200) cancers.
CONCLUSIONS: The total number of new cases of cancer in Europe appears to have increased by 300,000 since 2004. With an estimated 3.2 million new cases (53% occurring in men, 47% in women) and 1.7 million deaths (56% in men, 44% in women) each year, cancer remains an important public health problem in Europe and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant. Evidence-based public health measures exist to reduce the mortality of breast and colorectal cancer while the incidence of lung cancer, and several other forms of cancer, could be diminished by improved tobacco control.

Entities:  

Mesh:

Year:  2007        PMID: 17287242     DOI: 10.1093/annonc/mdl498

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  616 in total

1.  Polypsychopharmacy.

Authors:  S Sturges; M Brown
Journal:  Bull Menninger Clin       Date:  1975-05

Review 2.  L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Authors:  Wenjie Xia; Jie Wang; Youtao Xu; Feng Jiang; Lin Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

3.  The -4817 G>A (rs2238136) variant of the vitamin D receptor gene: a probable risk factor for colorectal cancer.

Authors:  Touraj Mahmoudi; Maral Arkani; Khatoon Karimi; Akram Safaei; Fatemeh Rostami; Elham Arbabi; Mohamad Amin Pourhoseingholi; Seyed Reza Mohebbi; Abdolrahim Nikzamir; Sara Romani; Shohreh Almasi; Maryam Abbaszadeh; Mohammad Vafaei; Mohammad Reza Zali
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

4.  Trends in incidence, tumour sites and tumour stages of oral and pharyngeal cancer in Northern Germany.

Authors:  Katrin Hertrampf; Jörg Wiltfang; Alexander Katalinic; Olaf Timm; Hans-Jürgen Wenz
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-14       Impact factor: 4.553

5.  No evidence for PML-RARa bcr1 fusion gene in colorectal cancer.

Authors:  Marta Herreros-Villanueva
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

6.  Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.

Authors:  Loukas Kontovinis; Konstantinos Laschos; Alexandra Karadimou; Charalambos Andreadis; Aristotelis Bamias; Panagiotis Paraskevopoulos; Meletios Dimopoulos; Konstantinos Papazisis
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

7.  Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland.

Authors:  I M Collins; F King; K O'Byrne
Journal:  Ir J Med Sci       Date:  2011-10-20       Impact factor: 1.568

8.  Alcohol consumption and endometrial cancer risk: the multiethnic cohort.

Authors:  Veronica Wendy Setiawan; Kristine R Monroe; Marc T Goodman; Laurence N Kolonel; Malcolm C Pike; Brian E Henderson
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

9.  'Quite an awkward situation to be in': perceptions of patients, carers and health and social care professionals of the supportive cancer care in British military personnel stationed in Germany.

Authors:  R Maguire; L Forbat; N Kearney; N Rowa-Dewar
Journal:  Support Care Cancer       Date:  2009-01-27       Impact factor: 3.603

10.  Yoga for Patients with Early Breast Cancer and its Impact on Quality of Life - a Randomized Controlled Trial.

Authors:  F Siedentopf; I Utz-Billing; S Gairing; W Schoenegg; H Kentenich; I Kollak
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-04       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.